Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

    January 2001 in “ Cancer investigation ”
    Alberto Gabizón
    Studysummary This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Correlation of Toxicity With Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma Cancer · 2000
    2. Doxil (Caelyx): An Exploratory Study with Pharmacokinetics in Patients with Hormone-Refractory Prostate Cancer Anti-cancer drugs · 2000